<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630722</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx180.003</article-id><article-id pub-id-type="publisher-id">ofx180.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Late Breaker Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daar</surname><given-names>Eric</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>DeJesus</surname><given-names>Edwin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Ruane</surname><given-names>Peter</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Crofoot</surname><given-names>Gordon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Oguchi</surname><given-names>Godson</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Creticos</surname><given-names>Catherine</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Rockstroh</surname><given-names>Jurgen K</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Molina</surname><given-names>Jean-Michel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Koenig</surname><given-names>Ellen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ya-Pei</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Andreatta</surname><given-names>Kristen</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Hiba</given-names></name><degrees>Pharm D</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Andrew</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Hal</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Quirk</surname><given-names>Erin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>1124&#x000a0;W. Carson St,, Harbor-UCLA Medical Center</institution>, <addr-line>Torrance, California</addr-line>;</aff><aff id="AF0002">
<label>2</label>
<institution>Orlando Immunology Center</institution>, <addr-line>Orlando, Florida</addr-line>;</aff><aff id="AF0003">
<label>3</label>
<institution>Ruane Clinical Research Group, Inc.</institution>, <addr-line>Los Angeles, California</addr-line>;</aff><aff id="AF0004">
<label>4</label>
<institution>The Crofoot Research Center</institution>, <addr-line>Houston, Texas</addr-line>;</aff><aff id="AF0005">
<label>5</label>
<institution>Midland Florida Clinical Research Center, LLC</institution>, <addr-line>Deland, Florida</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>Howard Brown Health Center</institution>, <addr-line>Chicago, Illinois</addr-line>;</aff><aff id="AF0007">
<label>7</label>
<institution>Department of Medicine I, Bonn University Hospital</institution>, <addr-line>Venusburg</addr-line>, <country>Germany</country>;</aff><aff id="AF0008">
<label>8</label>
<institution>Department of Infectious Diseases, Saint-Louis Hospital</institution>, <addr-line>Paris</addr-line>, <country>France</country>;</aff><aff id="AF0009">
<label>9</label>
<institution>Medicine, Inst.Domin Estudio Virologicos</institution>, <addr-line>Santo Domingo</addr-line>, <country>Dominican Republic</country></aff><aff id="AF0010">
<label>10</label>
<institution>Gilead Sciences</institution>, <addr-line>Foster City, California</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 228. Late Breaker Oral Abstracts</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S735</fpage><lpage>S735</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx180.003.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Boosted protease inhibitor regimens (bPIs) are effective and often used in HIV-infected individuals with difficulties with adherence, but they can have drug&#x02013;drug interactions and GI adverse effects. Bictegravir (B), a novel, potent integrase strand transfer inhibitor with a high barrier to resistance and low potential for drug&#x02013;drug interactions, was coformulated with the recommended nucleoside reverse transcriptase inhibitor backbone emtricitabine (FTC)/tenofovir alafenamide (F/TAF) and demonstrated high efficacy and tolerability in randomized studies in treatment-na&#x000ef;ve adults. This randomized Phase 3 study assesses efficacy and safety of switching to B/F/TAF from a multi-tablet regimen containing a&#x000a0;bPI.</p></sec><sec id="s2"><title>Methods</title><p>HIV-infected adults suppressed on regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their current bPI regimen or switch to open-label coformulated B/F/TAF (50/200/25&#x000a0;mg) once daily. Primary endpoint was proportion with HIV-1 RNA &#x02265;50 copies/mL (c/mL) at W48 (FDA snapshot). Noninferiority was assessed through 95.002% confidence intervals (CI) using a margin of 4%. Secondary endpoints included proportion with HIV-1 RNA &#x0003c;50 c/mL and safety measures at&#x000a0;W48.</p></sec><sec id="s3"><title>Results</title><p>A&#x000a0;total of 577 participants were randomized and treated with B/F/TAF (<italic>n =</italic> 290)&#x000a0;or current bPI regimens (<italic>n =</italic> 287): 17% women, 26% Black, median age 48&#x000a0;years. Most were receiving a bPI with FTC/TDF (85%) at screening. At W48, switching to B/F/TAF was noninferior to continuing bPI with 1.7% in each group having HIV-1 RNA &#x02265;50 c/mL (difference &#x02212;0.0%; 95.002% CI &#x02212;2.5% to 2.5%, <italic>P =</italic> 1.00); the proportion with HIV-1 RNA &#x0003c;50 c/mL was 92.1% in B/F/TAF vs. 88.9% in bPI. No participant on B/F/TAF developed resistance to study drugs. One participant on DRV/ritonavir + ABC/3TC developed a treatment-emergent L74V mutation. Incidence of grade 3 or 4 AEs was similar (B/F/TAF 4%, bPI regimens 6%). No renal discontinuations or tubulopathy cases occurred with B/F/TAF.</p></sec><sec id="s4"><title>Conclusion</title><p>Adults switching to B/F/TAF from a boosted PI maintained high rates of virologic suppression without resistance. B/F/TAF was safe and well tolerated.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>E.&#x000a0;Daar</bold>, Bristol-Myers Squibb: Consultant, Consulting fee. Gilead Sciences, Inc.: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Janssen: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Merck: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. Teva Pharmaceuticals: Consultant and Scientific Advisor, Consulting fee. ViiV: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research support. <bold>E. DeJesus</bold>, Abbott Laboratories; Achillion Pharmaceuticals, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffmann LaRoche, Idenix, Janssen, Merck, Pfizer, Sangamo, Taimed, Tobira, and Vertex: Grant Investigator, Research grant. Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Vertex: Scientific Advisor, Consulting fee. <bold>P. Ruane</bold>, Gilead: Investigator, Scientific Advisor and Shareholder, Consulting fee and Research support. Merck: Speaker&#x02019;s Bureau, Speaker honorarium. Boehringer: Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research support and Speaker honorarium. Janssen: Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research support and Speaker honorarium. Abbott: Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Research support and Speaker honorarium. Idenix: Investigator, Research support. ViiV: Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee and Speaker honorarium. BMS: Consultant, Investigator and Speaker&#x02019;s Bureau, Consulting fee, Research support and Speaker honorarium. <bold>G. Crofoot</bold>, Gilead: Investigator and Scientific Advisor, Advisory honorarium and Research grant. ViiV: Investigator and Scientific Advisor, Advisory honorarium, Research grant and Research support. <bold>C. Creticos</bold>, Thera Technologies and ViiV Healthcare: Scientific Advisor, Consulting fee. Gilead sciences, Merck, and ViiV Healthcare: Investigator, Research support. Pfizer: Speaker&#x02019;s Bureau, Speaker honorarium. <bold>J. K.&#x000a0;Rockstroh</bold>, Abbvie: Consultant and Investigator, Consulting fee and Speaker honorarium. Gilead: Consultant, Investigator and Scientific Advisor, Consulting fee and Speaker honorarium. ViiV: Scientific Advisor, Consulting fee. Janssen: Investigator and Speaker at educational event, Speaker honorarium. <bold>J. M.&#x000a0;Molina</bold>, Gilead, ViiV, Merck, Janssen, BMS and TEVA: Scientific Advisor, Speaker honorarium. <bold>Y. P.&#x000a0;Liu</bold>, Gilead: Employee and Shareholder, Salary and Shareholder. <bold>K. Andreatta</bold>, Gilead: Employee and Shareholder, Salary and Shareholder. <bold>H. Graham</bold>, Gilead Sciences: Employee and Shareholder, Salary. <bold>A. Cheng</bold>, Gilead: Employee and Shareholder, Salary. <bold>H. Martin</bold>, Gilead Sciences: Employee, Salary. <bold>E. Quirk</bold>, Gilead: Employee and Shareholder, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>